Van ECK Associates Corp Sells 1,107 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Van ECK Associates Corp trimmed its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 24.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,457 shares of the biopharmaceutical company’s stock after selling 1,107 shares during the period. Van ECK Associates Corp’s holdings in Amicus Therapeutics were worth $39,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of FOLD. Janus Henderson Group PLC increased its holdings in Amicus Therapeutics by 20.1% in the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after acquiring an additional 2,307,385 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Amicus Therapeutics by 583.4% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company’s stock valued at $25,640,000 after acquiring an additional 1,858,100 shares during the last quarter. Millennium Management LLC increased its holdings in Amicus Therapeutics by 1,758.9% in the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock valued at $18,790,000 after acquiring an additional 1,792,277 shares during the last quarter. William Blair Investment Management LLC increased its holdings in Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after acquiring an additional 1,477,084 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after acquiring an additional 1,192,489 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on FOLD shares. Morgan Stanley reduced their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. JPMorgan Chase & Co. lifted their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday. Cantor Fitzgerald lifted their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Bank of America lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Finally, Guggenheim lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Amicus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Price Performance

FOLD stock opened at $10.37 on Thursday. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The company has a 50-day moving average price of $11.07 and a 200 day moving average price of $10.61. The stock has a market cap of $3.10 billion, a PE ratio of -30.50 and a beta of 0.68.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $11,083,175. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,161,054.84. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,401 shares of company stock valued at $352,038. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.